Clinical Trials · NCT02221999
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients
- Phase
- Phase 2/Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- RenJi Hospital
- Enrollment
- 250
- Start date
- Sep 2013
- Locations
- 12 sites, China
- Primary endpoint
- pathological complete remission rate